Pfizer, NABP launch anticounterfeiting effort
NEW YORK — Last year, U.S. Customs and Border Protection seized $5.6 million worth of illegal pharmaceutical products, a 170% increase over 2005. Meanwhile, global sales of counterfeit medicines were estimated to be more than $75 billion last year, 90% more than in 2005.
In response, Pfizer and the National Association of Boards of Pharmacy announced Thursday the launch of an effort to educate patients on how to safely buy medicines online and about the risks of counterfeit drugs.
"Authentic prescription medicines are manufactured with pure ingredients in clean facilities, under a highly regulated, quality-controlled process, but counterfeit medicines are often produced in unsanitary conditions by people without any medical or scientific background," Pfizer senior director of global security for the Americas region Patrick Ford said. "Law-enforcement officials have found fake medicines being made in bathrooms and outdoors in the vicinity of farm animals."
Counterfeit medicines can be extremely dangerous and have been found to contain substances, such as rat poison and lead paint, as well as not having the correct, Food and Drug Administration-approved amount of active pharmaceutical ingredient. Counterfeits of all types of drugs, branded and generic, are known to exist, with Pfizer’s erectile dysfunction drug Viagra (sildenafil citrate) being a particularly popular target.
"Counterfeiters who sell fake medicines online prey on ingrained online buying behavior, in which consumers disregard warnings signs and prioritize price and convenience," NABP executive director Carmen Catizone said. "As a result, counterfeiters sell fake medicines through deceptive practices and typically don’t insist that patients provide a valid prescription, which is required by law."
The FDA also announced Thursday that it completed the International Internet Week of Action, also known as Operation Pangea IV, a cooperative effort with other regulatory and international partners aimed at combatting counterfeit and other illegal drugs and devices on the Internet. The IIWA’s goal was to raise public awareness of the dangers of buying drugs and devices on the Internet illegally, identify their producers and distributors and target them with civil and criminal action, seizing the products and removing them from the supply chain. Nearly 1,000 websites illegally selling drugs to U.S. consumers were targeted, the FDA said.
"The FDA will continue to work closely with our domestic and international law enforcement and regulatory partners to protect consumers from unapproved and potentially harmful products sold over the Internet," FDA associate commissioner for regulatory affairs Dara Corrigan said. "We will continue to aggressively pursue those who sell products which may pose a significant risk to consumer health."
Everyone can agree that the production of counterfeit medicines is harmful to Americans and should be stopped. However, many Americans cannot afford the high prescription drug costs in the United States. According to a recent Consumer Reports study, many Americans have been forced to exercise risky prescription practices such as cutting their medications in half or skipping doses in order to cut costs. However, through drug importation from licensed, legitimate Canadian and other international online pharmacies Americans can buy their brand name medications at 50-80 percent less than in U.S. pharmacies. These legitimate online pharmacies sell safe prescription drugs and ALWAYS require a valid doctor’s prescription. RxRights is a national coalition of individuals and organizations dedicated to promoting and protecting American consumer access to sources of safe, affordable prescription drugs. The Coalition is encouraging consumers to take action now by sending letters to Capitol Hill and the White House to protect access to drug importation from licensed, legitimate Canadian and other international online pharmacies. For more information or to voice your concern, visit www.RxRights.org.
J&J/Merck Consumer now officially part of McNeil
FORT WASHINGTON, Pa. — McNeil-PPC announced Wednesday that the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals joint venture has been completed.
The joint venture will be renamed McNeil Consumer Pharmaceuticals and will continue to market products under the Pepcid, Mylantq and Mylicon brands.
In addition, Johnson & Johnson, through its McNeil Consumer Healthcare Division (McNeil Canada) has acquired from Merck Canada its partnership interest in the Canadian joint venture. McNeil Canada will continue to market and sell Pepcid, 222 and Fleet Enema in Canada.
Ownership of the manufacturing facility located in Lancaster, Pa., also will transfer to McNeil-PPC.
Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.
No comments found
Inaugural Walgreens health conference addresses care continuum efficiencies
DEERFIELD, Ill. — Representatives from leading health systems came together over the past two days to discuss evolving efforts in coordinated patient care at the first Walgreens Health Systems Executive Client Forum, Walgreens stated Thursday.
The event featured presentations from health care thought leaders, health system representatives and Walgreens executives. Throughout the forum, attendees participated in activities to identify and share best practices on how health systems can improve quality of care, reduce readmissions and drive cost savings for patients and payers through innovative pharmacy and wellness initiatives.
Jefferson School of Population Health dean, David Nash, spoke on the role of population health efforts in driving outcomes and moderated a panel discussion on improving coordination across the care continuum, limiting patient readmissions and ensuring that clinicians operate to the extent of their licensure in order to improve access in the health care system. Donna Shalala, president of the University of Miami and former U.S. secretary of Health and Human Services provided the keynote address to attendees at the two-day event.
“As millions of new individuals enter a healthcare system that is adapting to evolving patient needs, new reimbursement models and elements of health reform, the benefits of bringing innovators and thought leaders together was powerful," stated Katie Lestan, Walgreens divisional VP, health systems. “Walgreens network of more than 8,000 pharmacy and health-and-wellness locations puts us in close contact with thousands of healthcare institutions and providers across the nation. This in turn puts us in a unique position to assemble health leaders to strategize on lowering costs and improving outcomes for patients and payers.”
In the past year, Walgreens publicly announced a number of efforts with health systems across the country. Notable relationships include the development of a chronic care coordination program between Walgreens pharmacists and Northwestern Memorial Health Care physicians in Chicago; and the formation of coordinated care arrangements between Take Care Clinics at select Walgreens and the Louisiana State University Health Sciences Center and LSU Healthcare Network, as well as with Ochsner Health System in New Orleans and with Memorial Health System in Jacksonville, Fla.
No comments found